Emerging PCSK9 inhibitors for treating dyslipidaemia: Buttressing the gaps in coronary prevention

Expert Opinion on Emerging Drugs

Volumn 20, Issue 2, 2015, Pages 299-312

  Page, Michael M ^a   Watts, Gerald F ^a,b  

^a ROYAL PERTH HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Alirocumab; Bococizumab; Evolocumab; Familial hypercholesterolemia; Proprotein convertase subtilisin kexin type 9 inhibitors; Statins

Indexed keywords

ALIROCUMAB; BOCOCIZUMAB; EVOLOCUMAB; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MONOCLONAL ANTIBODY; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 INHIBITOR; UNCLASSIFIED DRUG; PCSK9 PROTEIN, HUMAN; SERINE PROTEINASE;

CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSLIPIDEMIA; FAMILIAL HYPERCHOLESTEROLEMIA; GENETIC DISORDER; HUMAN; HYPERLIPOPROTEINEMIA; IMMUNOGENICITY; REVIEW; TREATMENT WITHDRAWAL; ANIMAL; ANTAGONISTS AND INHIBITORS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; COMPLICATION; DRUG DESIGN; DYSLIPIDEMIAS; MORTALITY;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; DRUG DESIGN; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 84930021340     PISSN: 14728214     EISSN: 17447623     Source Type: Journal    
DOI: 10.1517/14728214.2015.1035709     Document Type: Review

References (97)

1. Mendis S, Puska P, Norrving B. editors. Global atLas on cardiovascuLar disease prevention and control. Geneva, SwitzerLand: World Health Organisation; 2011
2. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guiDeline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascuLar risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice GuiDelines. CircuLation 2014;129:S1-45
3. Reiner Z, Catapano AL, De Backer G, et al. ESC/EAS GuiDelines for the management of dyslipiDaemias: the Task Force for the management of dyslipiDaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818
4. Ference BA, Mahajan N the role of early LDL lowering to prevent the onset of atherosclerotic disease. Curr Atheroscler Rep 2013;15:312
5. Eckel RH, Jakicic JM, Ard JD, et al. 2013 AHA/ACC guiDeline on lifestyle management to reduce cardiovascuLar isk: A report of the American College of Cardiology/American Heart Association Task Force on Practice GuiDelines. CircuLation 2014;129:S76-99
6. Assmann G, Cullen P, Schulte H the Munster Heart Study: results of followup at 8 years. Eur Heart J 1998;19(Suppl A):A2-11
7. Martin MJ, Browner WS, Hulley SB, et al. Serum cholesterol, blood pressure and mortality: implications from a cohort of 361 662 men. Lancet 1986;328:933-6
8. Burnett JR, Be DA, Hooper AJ, Hegele RA. Clinical utility gene card for: familial hypobetalipoproteinaemia (APOB). Eur J Hum Genet 2012;20. AvaiLable from: http://www.nature.com/ejhg/journal/vaop/ncurrent/full/ejhg2014225a.html doi: 10.1038/ejhg.2012.85
9. SniDerman AD, Williams K, Contois JH, et al. A meta-Analysis of low-Density lipoprotein cholesterol, non-high-Density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascuLar risk. Circ Cardiovasc Qual Outcomes 2011;4:337-45
10. Watts GF, Gidding S, Wierzbicki AS, et al. Integrated guiDance on the care of familial hypercholesteroLaemia from the International FH FounDation. Int J Cardiol 2014;171:309-25
11. Keen HI, Krishnarajah J, Bates TR, Watts GF. Statin myopathy: the fly in the ointment for the prevention of cardiovascuLar disease in the 21st century? Expert Opin Drug Saf 2014;13:1227-39
12. Leren TP. Sorting an LDL receptor with bound PCSK9 to intracelluLar DegraDation. Atherosclerosis 2014;237:76-81
13. Dadu RT, BalLantyne CM. Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol 2014;11:563-75
14. SeiDah NG, Awan Z, Chretien M, Mbikay M. PCSK9: A key moduLator of cardiovascuLar health. Circ Res 2014;114:1022-36
15. Davignon J. Beneficial cardiovascuLar pleiotropic effects of statins. CircuLation 2004;109:III39-43
16. Baigent C, BLackweL, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-Analysis of Data from 170 ,000 participants in 26 randomised trials. Lancet 2010;376:1670-81
17. LinDen F, Domschke G, Erbel C, et al. InfLammatory therapeutic targets in coronary atherosclerosis-from molecuLar biology to clinical application. Front Physiol 2014;5:455
18. Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascuLar outcomes: A systematic review and meta-Analysis. Lancet 2010;375:1875-84
19. Lee M, Saver JL, Towfighi A, et al. Efficacy of fibrates for cardiovascuLar risk reduction in persons with atherogenic dyslipiDemia: A meta-Analysis. Atherosclerosis 2011;217:492-8
20. Landray MJ, Haynes R, HopeweJC, et al. Effects of extenDed-release niacin with Laropiprant in high-risk patients. N Engl J Med 2014;371:203-12
21. Cannon CP; On behalf of the IMPROVEIT Investigators. IMPROVE-IT Trial: A comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascuLar outcomes after acute coronary syndromes. In: Proceedings of the American Heart Association Scientific Sessions; Chicago, USA; 2014. AvaiLable from: http://my. americanheart.org/professional/Sessions/ScientificSessions/ScienceNews/SS14-Late-Breaking-Clinical-Trials-UCM-468855-Article.jsp
22. Koschinsky M, Boffa M. Lipoprotein(a) as a therapeutic target in cardiovascuLar disease. Expert Opin Ther Targets 2014;18:747-57
23. NorDestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascuLar risk factor: current status. Eur Heart J 2010;31:2844-53
24. Koschinsky ML, Boffa MB. Lipoprotein (a): An important cardiovascuLar risk factor and a clinical conundrum. Endocrinol Metab Clin North Am 2014;43:949-62
25. Nestel PJ, Barnes EH, Tonkin AM, et al. PLasma lipoprotein(a) concentration predicts future coronary and cardiovascuLar events in patients with stable coronary heart disease. Arterioscler Thromb Vasc Biol 2013;33:2902-8
26. ODonoghue ML, Morrow DA, Tsimikas S, et al. Lipoprotein(a) for risk assessment in patients with established coronary artery disease. J Am CoCardiol 2014;63:520-7
27. Bos S, Yayha R, Van Lennep JE. Latest Developments in the treatment of lipoprotein(a). Curr Opin Lipidol 2014;25:452-60
28. Leebmann J, Roeseler E, Julius U, et al. Lipoprotein apheresis in patients with maximally tolerated lipid-lowering therapy, lipoprotein(a)-hyperlipoproteinemia, and progressive cardiovascuLar disease: prospective observational multicenter study. CircuLation 2013;128:2567-76
29. Benn M, Watts GF, Tybjaerg-Hansen A, NorDestgaard BG. Familial hypercholesterolemia in the Danish general popuLation: prevalence, coronary artery disease, and cholesterol-lowering medication. J Clin Endocrinol Metab 2012;97:3956-64
30. Sjouke B, Kusters DM, Kindt I, et al. Homozygous autosomal dominant hypercholesteroLaemia in the NetherLands: prevalence, genotypephenotype reLationship, and clinical outcome. Eur Heart J 2015;36(9):560-5
31. Page MM, Ekinci EI, Jones RM, et al. Liver transpLantation for the treatment of homozygous familial hypercholesteroLaemia in an era of emerging lipid-lowering therapies. Intern Med J 2014;44:601-4
32. Besseling J, Kindt I, Hof M, et al. Severe heterozygous familial hypercholesterolemia and risk for cardiovascuLar disease: A study of a cohort of 14 ,000 mutation carriers. Atherosclerosis 2014;233:219-23
33. Joy TR, Hegele RA. Narrative review: statin-reLated myopathy. Ann Intern Med 2009;150:858-68
34. Mancini GB, Tashakkor AY, Baker S, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus upDate. Can J Cardiol 2013;29:1553-68
35. Heeschen C, Hamm CW, Laufs U, et al. Withdrawal of s atins increases event rates in patients with acute coronary syndromes. CircuLation 2002;105:1446-52
36. Wei L, Wang J, Thompson P, et al. Adherence to statin teatment and readmission of patients after myocardial infarction: A six year follow up study. Heart 2002;88:229-33
37. Rasmussen JN, Chong A, Alter DA. ReLationship between adherence to eviDence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007;297:177-86
38. Ho PM, Magid DJ, Shetterly SM, et al. Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease. Am Heart J 2008;155:772-9
39. Kashani A, Phillips CO, Foody JM, et al. Risks associated with statin therapy: A systematic overview of randomized clinical trials. CircuLation 2006;114:2788-97
40. Needham M, Mastaglia FL. Statin myotoxicity: A review of genetic susceptibility factors. Neuromuscul Disord 2014;24:4-15
41. Zhang H, Plutzky J, Skentzos S, et al. Discontinuation of statins in routine care settings: A cohort study. Ann Intern Med 2013;158:526-34
42. Simons LA, Ortiz M, Calcino G. Long term persistence with statin therapy-experience in Australia 2006-2010. Aust Fam Physician 2011;40:319-22
43. McGinnis B, Olson KL, Magid D, et al. Factors reLated to adherence to statin therapy. Ann Pharmacother 2007;41:1805-11
44. Bruckert E, Hayem G, Dejager S, et al. Mild to moDerate muscuLar symptoms with high-dosage statin therapy in hyperlipiDemic patients-The PRIMO study. Cardiovasc Drugs Ther 2005;19:403-14
45. Backes JM, Venero CV, Gibson CA, et al. Effectiveness and tolerability of every-other-Day rosuvastatin dosing in patients with prior statin intolerance. Ann Pharmacother 2008;42:341-6
46. Meek C, Wierzbicki AS, Jewkes C, et al. Daily and intermittent rosuvastatin 5 mg therapy in statin intolerant patients: An observational study. Curr Med Res Opin 2012;28:371-8
47. Mampuya WM, Frid D, Rocco M, et al. Treatment strategies in patients with statin intolerance: the CleveLand Clinic experience. Am Heart J 2013;166:597-603
48. Joy TR, Monjed A, Zou GY, et al. N-of-1 (single-patient) trials for statinreLated myalgia. Ann Intern Med 2014;160:301-10
49. Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354:1264-72
50. AbifaDel M, Varret M, Rabes J-P, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003;34:154-6
51. Mabuchi H, Nohara A, Noguchi T, et al. Genotypic and phenotypic features in homozygous familial hypercholesterolemia caused by proprotein convertase subtilisin/kexin type 9 (PCSK9) gain-of-function mutation. Atherosclerosis 2014;236:54-61
52. Tavori H, Fan D, BLakemore JL, et al. Serum proprotein convertase subtilisin/kexin type 9 and cesurface low-Density lipoprotein receptor: eviDence for a reciprocal reguLation. CircuLation 2013;127:2403-13
53. Zhang D-W, Lagace TA, Garuti R, et al. Binding of proprotein convertase subtilisin/kexin type 9 to epiDermal growth factor-like repeat A of low Density lipoprotein receptor Decreases receptor recycling and increases DegraDation. J Biol Chem 2007;282:18602-12
54. Urban D, Poss J, Bohm M, Laufs U. Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipiDemia and atherosclerosis. J Am CoCardiol 2013;62:1401-8
55. Fitzgerald K, Frank-Kamenetsky M, Shulga-Morskaya S, et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: A randomised, single-blind, pLacebo-controlled, phase 1 trial. Lancet 2014;383:60-8
56. Clinicaltrials.gov. A study of LY3015014 in participants with high cholesterol [Internet]. US National Institutes of Health; 2014. AvaiLable from: https://clinicaltrials.gov/ct2/show/study/NCT01890967?term=ly3015014&rank=2 [Cited 7 January 2015]
57. Koren MJ, Giugliano RP, Raal FJ, et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial. CircuLation 2014;129:234-43
58. Blom DJ, HaLa T, Bolognese M, et al. A 52-week pLacebo-controlled trial of evolocumab in hyperlipiDemia. N Engl J Med 2014;370:1809-19
59. Roth EM, Taskinen MR, Ginsberg HN, et al. Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: Results of a 24-week, double-blind, randomized Phase 3 trial. Int J Cardiol 2014;176:55-61
60. GauDet D, Kereiakes DJ, McKenney JM, et al. Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). Am J Cardiol 2014;114:711-15
61. Lewington S, Whitlock G, CLarke R, et al. Blood cholesterol and vascuLar mortality by age, sex, and blood pressure: A meta-Analysis of individual Data from 61 prospective studies with 55 ,000 vascuLar Deaths. Lancet 2007;370:1829-39
62. Amarenco P, BogoussLavsky J, CalLahan A, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-59
63. McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: A meta-Analysis of 31 randomized controlled trials. Stroke 2012;43:2149-56
64. McGuinness B, OHare J, Craig D, et al. Cochrane review on Statins for the treatment of Dementia. Int J Geriatr PsycHi ATry 2013;28:119-26
65. Everett BM, Mora S, Glynn RJ, et al. Safety profile of subjects treated to very low low-Density lipoprotein cholesterol levels ( 30 mg/dl) with rosuvastatin 20 mg Daily (from JUPITER. Am J Cardiol, 2014. 114. 1682-9
66. Roth EM, McKenny JM, Hanotin C, et al. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med 2012;367:1891-900
67. Raal FJ, Stein EA, Dufour R, et al. PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesteroLaemia: results of a randomised, double-blind, pLacebocontrolled trial. Lancet 2015;385(9965):331-40
68. Raal FJ, Honarpour N, Blom DJ, et al. Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesteroLaemia: results of a randomised, double-blind, pLacebocontrolled trial. Lancet 2015;385(9965):341-50
69. HaraDa-Shiba M, Kishimoto I, Makino H, et al. Efficacy of evolocumab (AMG 145) in patients with PCSK9 gain-of-function mutations [abstract]. Atherosclerosis 2014;235:e11
70. Stroes E, Colquhoun D, SulliVan D, et al. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, pLacebo-controlled phase 3 clinical trial of evolocumab. J Am CoCardiol 2014;63:2541-8
71. Cho L, Rocco M, Colquhoun D, et al. Design and rationale of the GAUSS-2 study trial: A double-blind, ezetimibecontrolled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy. Clin Cardiol 2014;37:131-9
72. Moriarty PM, Thompson PD, Cannon CP, et al. Odyssey Alternative: Efficacy and safety of the proproptein convertase subtilisin/kexin type 9 monoclonal antibody, alirocumab, versus ezetimibe, in patients with statin intolerance as Defined by a pLacebo run-in and statin rechallenge arm. In: Proceedings of the 2014 American Heart Association Scientific Sessions; Chicago, USA; 2014. AvaiLable from: http://my. americanheart.org/idc/groups/ahamahpublic/@ wcm/@sop/@scon/documents/downloaDable/ucm-469597.pdf
73. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascuLar events. N Engl J Med 2015. [Epub ahead of print]
74. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascuLar events. N Engl J Med 2015. [Epub ahead of print]
75. Cuchel M, Meagher EA, du Toit Theron H, et al. Efficacy and safety of a microsomal triglyceriDe transfer protein inhibitor in patients with homozygous familial hypercholesteroLaemia: A single-Arm, open-Label, phase 3 study. Lancet 2013;381:40-6
76. Hooper AJ, Burnett JR, Watts GF. Contemporary aspects of the biology and therapeutic reguLation of the microsomal triglyceriDe transfer protein. Circ Res 2015;116:193-205
77. Visser ME, Wagener G, Baker BF, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-Density lipoprotein cholesterol in high-risk statin-intolerant patients: A randomized, double-blind, pLacebo-controlled trial. Eur Heart J 2012;33:1142-9
78. McGowan MP, Tardif J-C, Ceska R, et al. Randomized, pLacebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One 2012;7:e49006
79. Stein EA, Dufour R, Gagne C, et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, pLacebocontrolled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. CircuLation 2012;126:2283-92
80. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesteroLaemia: A randomised, double-blind, pLacebo-controlled trial. Lancet 2010;375:955-1052
81. Targher G, Day CP, Bonora E. Risk of cardiovascuLar disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010;363:1341-50
82. Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: A randomized controlled trial. JAMA 2011;306:2099-109
83. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363:2406-15
84. RaDer DJ, Ruotolo G, Kane JP, et al. Effects of the cholesteryl ester transfer protein inhibitor, evacetrapib, administered as monotherapy or in combination with statins on cholesterol efflux and HDL particles in patients with dyslipiDemia. In: Proceedings of the American Heart Association Scientific Sessions; Chicago, USA; 2014. AvaiLable from: http://aha. scientificposters.com/epsAbstractAHA. cfm?id=14
85. Rohatgi A, Khera A, Berry JD, et al. HDL cholesterol efflux capacity and inciDent cardiovascuLar events. N Engl J Med 2014;371:2383-93
86. Dong B, Singh AB, Fung C, et al. CETP inhibitors downreguLate hepatic LDL receptor and PCSK9 expression in vitro and in vivo through a SREBP2 DepenDent mechanism. Atherosclerosis 2014;235:449-62
87. Schwartz GG, Olsson AG, Abt M, et al. Effects of Dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089-99
88. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22
89. Nikolic D, Mikhailidis DP, Davidson MH, et al. ETC-1002: A future option for lipid disorDers? Atherosclerosis 2014;237:705-10
90. Chaparro-Riggers J, Liang H, DeVay RM, et al. Increasing serum halflife and extending cholesterol lowering in vivo by engineering an antibody with pH-sensitive binding to PCSK9. J Biol Chem 2012;287(14):11090-7
91. Vogt A, Parhofer KG the potential of mipomersen, an apoB synthesis inhibitor, to reduce necessity for LDL-Apheresis in patients with heterozygous familial hypercholesterolemia and coronary artery disease. Expert Opin Pharmacother 2013;14:691-7
92. Parhofer KG. How winew medications affect the lipoprotein apheresis situation in Germany? Atheroscler Suppl 2013;14:71-2
93. BalLantyne CM, Neutel J, Cropp A, et al. Efficacy and safety of bococizumab (RN316/PF-04950615), a monoclonal antibody against proprotein convertase subtilisin/kexin type 9 in statin-treated hypercholesterolemic subjects: results from a randomized, pLacebo-controlled, dose-ranging study (NCT: 01592240). In: Proceedings of the American College of Cardiology Scientific Sessions; Washington DC, USA; 2014. AvaiLable from: http://dx.doi. org/10.1016/S0735-1097(14)61374-7
94. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-Density lipoprotein cholesterol in patients with heterozygous familial hypercholesteroLaemia on stable statin dose with or without ezetimibe therapy: A phase 2 randomised controlled trial. Lancet 2012;380:29-36
95. Tingley W, Luca D, Leabman M, et al. Effects of RG7652, a fully human mAb against proprotein convertase subtilisin/kexin type 9, on LDL-C: A Phase I, randomised, double-blind, pLacebocontrolled, single-And multiple-dose study. Eur Heart J 2013;34:767
96. Stein EA, KasichayanuLa S, Turner T, et al. LDL cholesterol reduction with BMS-962476, an adnectin inhibitor of PCSK9: results of a single ascending dose study [abstract]. J Am CoCardiol 2014;63:61372-3
97. Page MM, Stefanutti C, SniDerman A, Watts GF. Recent adVances in the unDerstanding and care of familial hypercholesteroLaemia: significance of the biology and therapeutic reguLation of proprotein convertase subtilisin/kexin type 9. Clin Sci 2015